Semnurpharma - Getting back to normalSemnurpharmaSemnurpharmaSemnurpharma

Getting back to normal

  • About
    • Overview
    • Leadership Team
    • Board of Directors
    • Our Culture
  • Partners
  • Chronic Back Pain
    • Chronic Back Pain
    • SP-102 (SEMDEXA™)
    • About our Studies
      • Phase 3 C.L.E.A.R.-2 Study
      • Phase 3 C.L.E.A.R. Study
      • Phase 2 Repeat Dose Study – SP102-03
      • Phase 1 PK/PD and Safety Study – SP-102
      • Pre-Clinical Study – SP-102
  • Science
    • Technology
    • Publications
    • Clinical Trials
  • Investors
    • Investor Overview
    • Presentation
    • News and Events
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
  • Join Our Team
  • Contact Us

Leadership

07
Aug
Date August 7, 2024

Henry Ji, PhD

Henry Ji brings 25+ years of experience in the biotechnology and life sciences industry. Dr. Ji is c...
Read More
Author uferes@scilexholding.com
07
Aug
Date August 7, 2024

Jaisim Shah

Jaisim Shah has over 30 years industry success in leading product development & commercializing...
Read More
Author uferes@scilexholding.com
06
Aug
Date August 6, 2024

Stephen Ma

Stephen Ma serves as the Chief Operating Officer, Chief Financial Officer and Senior Vice President...
Read More
Author uferes@scilexholding.com
05
Aug
Date August 5, 2024

Dmitri Lissin, M.D.

Dmitri Lissin currently serves as Chief Medical Officer and Senior Vice President, of Semnur Pharmac...
Read More
Author uferes@scilexholding.com
04
Aug
Date August 4, 2024

Suketu D. Desai, PhD

Suketu D. Desai, Ph.D. has 25+ years of experience in the Biologics and Pharmaceutical Industry. Suk...
Read More
Author uferes@scilexholding.com
03
Aug
Date August 3, 2024

Steve Lincoln

Steve Lincoln serves as General Counsel, Chief Compliance Officer for Semnur Pharmaceuticals. Prior...
Read More
Author uferes@scilexholding.com
02
Aug
Date August 2, 2024

Gigi DeGuzman

Gigi DeGuzman is a seasoned professional with over 25 years of experience in human resources, operat...
Read More
Author uferes@scilexholding.com

 

  • Overview
  • Partners
  • Our Culture
  • Product
  • Publications
  • Join Our Team
  • Presentation
  • Contact Us

Connect, follow and have a conversation with us

  • 960 San Antonio Road, Palo Alto, CA, 94303
  • (650) 516-4310
  • info@semnurpharma.com

Privacy Policy | Terms of Use | © 2025 All rights reserved.

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination

Check Our Press Release

Scilex Holding

Semnur Pharmaceuticals

Denali Capital

Reference:
@srinipillay 2016:https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

… heavy objects, or some other non-specific back injury.

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

The overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is approximately 12.1 million across all Medicare and private coverage patients, with lumbar radiculopathy/sciatica procedures comprising approximately 88% of all ESIs administered, according to a proprietary study by Syneos Health. *

References:
*  Syneos Health

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537